Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
No matter your therapeutic area of research, Thermo Fisher Scientific provides a wide array of products and profiling services to support your drug discovery and development needs. From protein kinases, GPCR, nuclear receptors, ion channels and more, we have a long history of providing high-quality products, with the service and support you expect from a market leader in drug development.
To help get you started on your journey to developing the next promising drug candidate or kinase inhibitor, here are a handful of the most-referenced Invitrogen protein kinase products for each therapeutic area. Alternatively, you can go straight to our selection and ordering tool.
Don’t see the protein kinase products or services you are looking for? Let our team of experts meet with you to find the best solution for your drug discovery and development needs at thermofisher.com/askdiscovery.
Cancer represents the largest research area currently being studied in any field of science and as such the discovery and development of kinase inhibitors that target cellular signaling responsible for tumor development, angiogenesis, cancer progression and metastasis, is inherent in anticancer prevention and treatments.
Thermo Fisher Scientific offers over 490 purified kinase proteins for therapeutic research and over 350 functional kinases that have been cited for cancer research in over 140,000 published papers.
To better understand the overall Thermo Fisher Scientific aim of pursuing a life without cancer view resources here.
See the full list of mutants and kinases for cancer research
Go to the kinase selection and ordering tool
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
EGFR (ErbB1) | 15274 | ✓ | PV3872 |
MET (CMET) | 8799 | ✓ | PV3143 |
SRC | 8011 | ✓ | P3044 |
MAPK3 (ERK1) | 7085 | PV3311 | |
ROS1 | 6245 | PV3814 | |
ERBB2 (HER2) | 4845 | PV3366 | |
BRAF | 4187 | ✓ | PV3848 |
ATM | 3774 | ||
ABL1 | 3525 | ✓ | P3049 |
BCR | 3425 | ||
CDK4 (cyclin D1) | 3187 | ✓ | PV4400 |
PTK2 (FAK) | 3000 | ✓ | PV3832 |
YES1 | 2955 | A15557 | |
CDK2/Cyclin A | 2869 | ✓ | PV3267 |
AKT1 (PKB alpha) | 2560 | P2999 | |
ALK | 2362 | ✓ | PV3867 |
KIT | 2072 | ✓ | P3081 |
ATR | 2040 | ||
RET | 1806 | ✓ | PV3819 |
PDK1 | 1763 | P3001 | |
CHEK1 (CHK1) | 1756 | P3040 | |
JAK2 | 1724 | ✓ | PV4210 |
CDK6/Cyclin D1 | 1670 | PV4401 | |
ABL2 (ARG) | 1636 | PV3266 | |
ErbB3 | 1588 | ||
CHEK2 (CHK2) | 1557 | PV3367 | |
MAPK1 (ERK2) | 1530 | PV3313 | |
MERTK (cMER) | 1329 | PV3627 | |
MERTK (cMER) A708S | 1322 | PV6325 | |
LKB1 | 1305 | ||
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
The leading cause of death worldwide, cardiovascular diseases (CVDs) impacts all corners of the globe from industrialized nations to developing countries. Further complicated by the concurrent growth in common risk factors for cardiovascular disease such as obesity and diabetes, the need to better understand how the disease progresses and the development of novel therapeutic treats is vital.
As wide variety of conditions can lead to heart disease including atherosclerosis, heart infections and structural or congenital defects, cardiovascular drug development programs are often quite complex and require multidisciplinary approaches. Novel pharmacological strategies that target specific receptors or proteins involved in CVDs are required for the safe and effective treatment and prevention of cardiovascular disease.
Thermo Fisher Scientific has a wide variety of cardiovascular targets to help advance your research needs.
Thermo Fisher Scientific offers over 490 purified protein kinases for therapeutic research and over 210 functional kinases that have been cited for cancer research in over 3,300 published papers.
See the full list of mutants and kinases for cardiovascular research
Go to the kinase selection and ordering tool
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 679 | PV3814 | |
MAPK3 (ERK1) | 280 | PV3311 | |
MET (CMET) | 255 | ✓ | PV3143 |
SRC | 213 | ✓ | P3044 |
EGFR (ErbB1) | 155 | ✓ | PV3872 |
YES1 | 86 | A15557 | |
ABL2 (ARG) | 61 | PV3266 | |
KDR (VEGFR2) | 58 | PV3660 | |
KIT | 56 | ✓ | P3081 |
AKT1 (PKB alpha) | 55 | P2999 | |
CSF1R (FMS) | 51 | PV3249 | |
MAPK8 (JNK1) | 49 | PV3319 | |
LKB1 | 46 | ||
PDK1 | 45 | P3001 | |
JAK2 | 43 | ✓ | PV4210 |
MAPK1 (ERK2) | 43 | PV3313 | |
PTK2 (FAK) | 43 | ✓ | PV3832 |
ATM | 36 | ||
MERTK (cMER) | 34 | PV3627 | |
ABL1 | 32 | ✓ | P3049 |
AKT2 (PKB beta) | 27 | PV3184 | |
p70S6K | 27 | PV6325 | |
ULK1 | 27 | PV6430 | |
ROCK1 | 26 | PV3691 | |
TEK (TIE2) | 26 | ✓ | PV3628 |
EIF2AK2 (PKR) | 23 | PV4821 | |
ERBB2 (HER2) | 23 | PV3366 | |
ERN1 | 22 | A30971 | |
IGF1R | 21 | PV3250 | |
FYN | 20 | ✓ | P3042 |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
With a significant change in the average age of the world’s population, there has been a concerted shift in research focus into CNS disorders, like Parkinson’s disease, multiple sclerosis and Alzheimer’s disease. Historically, CNS research has focused on targeting extracellular receptors and their respective signaling pathways. Recent advances in antibodies, vaccines, interfering RNA, and other biological therapeutics have yielded promising treatment options for CNS disorders.
Thermo Fisher Scientific offers over 490 purified kinase proteins and paired assays and was the first to commercially offer purified full-length LRRK2 protein—key in Parkinson’s disease research.
We have over 280 kinases cited in over 7,400 published research papers. See the list of kinases for Alzheimer’s disease research, multiple sclerosis research, Parkinson’s disease research, and schizophrenia research below.
For more information regarding Thermo Fisher Scientific’s role in helping researchers unlock the mystery of Parkinson’s disease visit our resources here
See the full list of mutants and kinases for CNS disorders research
Go to the kinase selection and ordering tool
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 123 | PV3814 | |
CDK5/p25 | 109 | PV4676 | |
MAPK3 (ERK1) | 78 | PV3311 | |
SRC | 69 | ✓ | P3044 |
MET (CMET) | 62 | ✓ | PV3143 |
FYN | 51 | ✓ | P3042 |
ABL2 (ARG) | 38 | PV3266 | |
LRRK2 | 26 | ✓ | PV4873 |
NTRK1 (TRKA) | 24 | PV3144 | |
DYRK1A | 22 | PV3785 | |
MERTK (cMER) | 22 | PV3627 | |
NTRK2 (TRKB) | 21 | PV3616 | |
PINK1 | 21 | ||
CDK1/Cyclin A1 | 19 | PV6280 | |
CDK2/Cyclin A | 18 | ✓ | PV3267 |
EGFR (ErbB1) | 18 | ✓ | PV3872 |
MAPK1 (ERK2) | 17 | PV3313 | |
MERTK (cMER) A708S | 15 | PV6325 | |
YES1 | 15 | A15557 | |
ABL1 | 14 | ✓ | P3049 |
CDK4 (cyclin D1) | 14 | PV4400 | |
LKB1 | 13 | ||
MAPK8 (JNK1) | 13 | PV3319 | |
MARK2 | 13 | PV3878 | |
EphB2 | 12 | PV3625 | |
PAK1 | 12 | PV3820 | |
GSK3B | 11 | PV3365 | |
ERN1 | 10 | A30971 | |
EIF2AK2 (PKR) | 9 | PV4821 | |
ERBB4 (HER4) | 9 | PV3626 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 367 | PV3814 | |
MAPK3 (ERK1) | 277 | PV3311 | |
MET (CMET) | 236 | ✓ | PV3143 |
SRC | 190 | ✓ | P3044 |
MERTK (cMER) A708S | 83 | PV6325 | |
EGFR (ErbB1) | 79 | ✓ | PV3872 |
JAK2 | 79 | ✓ | PV4210 |
YES1 | 79 | ✓ | A15557 |
ABL1 | 72 | ✓ | P3049 |
PINK1 | 69 | ||
LRRK2 | 68 | ✓ | PV4873 |
PDK1 | 66 | P3001 | |
FYN | 65 | ✓ | P3042 |
ABL2 (ARG) | 64 | PV3266 | |
KIT | 63 | ✓ | P3081 |
MAPK1 (ERK2) | 58 | PV3313 | |
NTRK2 (TRKB) | 57 | PV3616 | |
AKT1 (PKB alpha) | 56 | P2999 | |
EIF2AK2 (PKR) | 55 | PV4821 | |
TYK2 | 53 | PV4790 | |
CDK5/p25 | 52 | PV4676 | |
LKB1 | 52 | ||
BCR | 50 | ||
PTK2 (FAK) | 50 | ✓ | PV3832 |
JAK1 | 47 | PV4774 | |
CSF1R (FMS) | 43 | PV3249 | |
ULK1 | 43 | PV6430 | |
LYN A | 41 | ✓ | PV6448 |
TBK1 | 41 | PV3504 | |
ERN1 | 40 | A30971 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
PINK1 | 165 | ||
LRRK2 | 162 | ✓ | PV4873 |
ROS1 | 100 | PV3814 | |
MET (CMET) | 47 | ✓ | PV3143 |
MAPK3 (ERK1) | 33 | PV3311 | |
CDK5/p25 | 20 | PV4676 | |
GAK | 16 | A30973 | |
PLK2 | 15 | PV4204 | |
ABL2 (ARG) | 14 | PV3266 | |
SRC | 14 | ✓ | P3044 |
LRRK1 | 12 | ||
MERTK (cMER) | 11 | PV3627 | |
YES1 | 10 | A15557 | |
ERN1 | 9 | A30971 | |
PLK3 | 9 | PV3812 | |
MAPK1 (ERK2) | 8 | PV3313 | |
EGFR (ErbB1) | 7 | ✓ | PV3872 |
RET | 7 | ✓ | PV3819 |
ULK1 | 7 | PV6430 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
MET (CMET) | 215 | ✓ | PV3143 |
ERBB4 (HER4) | 185 | PV3626 | |
MAPK3 (ERK1) | 111 | PV3311 | |
NTRK2 (TRKB) | 108 | PV3616 | |
AKT1 (PKB alpha) | 102 | P2999 | |
SRC | 91 | ✓ | P3044 |
FYN | 63 | ✓ | P3042 |
ROS1 | 59 | PV3814 | |
CDK5/p25 | 53 | PV4676 | |
ErbB3 | 53 | ||
YES1 | 46 | A15557 | |
MAPK1 (ERK2) | 40 | PV3313 | |
EGFR (ErbB1) | 39 | ✓ | PV3872 |
ABL2 (ARG) | 25 | PV3266 | |
AKT3 (PKB gamma) | 22 | PV3185 | |
CAMK2A (CaMKII alpha) | 21 | PV3142 | |
FGFR1 | 21 | ✓ | PV3146 |
PAK1 | 21 | PV3820 | |
ERBB2 (HER2) | 20 | PV3366 | |
GSK3B | 20 | PV3365 | |
PTK2B (FAK2) | 20 | PV4567 | |
LIMK1 | 18 | PV4337 | |
AKT2 (PKB beta) | 17 | PV3184 | |
NTRK3 (TRKC) | 17 | PV3617 | |
PAK3 | 17 | PV3789 | |
TNIK | 17 | PV6427 | |
NTRK1 (TRKA) | 16 | PV3144 | |
PDK1 | 16 | P3001 | |
CASK | 15 | PV6271 | |
PINK1 | 14 | ||
RET | 14 | ✓ | PV3819 |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
As our understanding of the mechanisms that control inflammatory responses improve, there is has been an increased emphasis on developing the next-generation inflammation kinase inhibitors and other drug candidates. Inflammatory diseases are associated with numerous debilitating diseases, including arthritis, inflammatory bowel disease, Crohn’s disease, psoriasis and atherosclerosis.
Thermo Fisher Scientific offers over 490 purified protein kinases for therapeutic research and over 310 kinases that have been cited in over 27,000 published papers. Let our drug discovery products help you develop more effective anti-inflammatory drug candidates.
See the full list of mutants and kinases for inflammation research
Go to the kinase selection and ordering tool
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 4030 | PV3814 | |
MAPK3 (ERK1) | 2501 | PV3311 | |
SRC | 1683 | ✓ | P3044 |
MET (CMET) | 1314 | ✓ | PV3143 |
EGFR (ErbB1) | 1044 | ✓ | PV3872 |
JAK2 | 648 | ✓ | PV4210 |
MAPK8 (JNK1) | 606 | PV3319 | |
ABL2 (ARG) | 461 | PV3266 | |
SYK | 439 | PV3857 | |
JAK1 | 418 | PV4774 | |
MAPK1 (ERK2) | 390 | PV3313 | |
ATM | 374 | ||
YES1 | 371 | A15557 | |
EIF2AK2 (PKR) | 367 | PV4821 | |
KIT | 357 | ✓ | P3081 |
PTK2 (FAK) | 354 | ✓ | PV3832 |
IRAK, pelle | 351 | PV4403 | |
MERTK (cMER) | 326 | PV3627 | |
BCR | 309 | ||
MAP3K14 (NIK) | 301 | PV4902 | |
CSF1R (FMS) | 297 | PV3249 | |
AKT1 (PKB alpha) | 291 | P2999 | |
ABL1 | 276 | ✓ | P3049 |
LYN A | 258 | ✓ | PV6448 |
TBK1 | 249 | PV3504 | |
FYN | 233 | ✓ | P3042 |
PDK1 | 224 | P3001 | |
LCK | 218 | P3043 | |
CDK4 (cyclin D1) | 216 | PV4400 | |
JAK3 | 214 | PV3855 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
As the worldwide obesity rate continues to grow, there has been an increase emphasis on studying the complications associated with metabolic disorders, like type II diabetes and hyperlipidemia. The roles of cell surface receptors and their respective signaling pathways have become increasingly more important in metabolic research, as these receptors are vital in the regulation of insulin and glucagon secretion. As a result, developing fast-acting kinase inhibitors that can control the ways the body moderates metabolism and weight are at the forefront of many research endeavors.
Thermo Fisher Scientific offers over 490 purified protein kinases for therapeutic research and over 300 kinases that have been cited in over 14,000 published papers. See the list of kinases for diabetes research and hyperlipidemia research below.
See the full list of mutants and kinases for metabolic disorders research
Go to the kinase selection and ordering tool
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 2458 | PV3814 | |
MAPK3 (ERK1) | 1053 | PV3311 | |
MET (CMET) | 980 | ✓ | PV3143 |
SRC | 690 | ✓ | P3044 |
EGFR (ErbB1) | 566 | ✓ | PV3872 |
LKB1 | 397 | ||
PDK1 | 345 | P3001 | |
YES1 | 340 | A15557 | |
AKT1 (PKB alpha) | 339 | P2999 | |
MAPK8 (JNK1) | 293 | PV3319 | |
AKT2 (PKB beta) | 282 | PV3184 | |
ABL2 (ARG) | 268 | PV3266 | |
JAK2 | 254 | ✓ | PV4210 |
ERN1 | 235 | A30971 | |
MAP4K2 (GCK) | 233 | PV4211 | |
EIF2AK2 (PKR) | 227 | PV4821 | |
ATM | 198 | ||
p70S6K | 193 | PV6325 | |
CDK5/p25 | 173 | PV4676 | |
INSR | 169 | PV3781 | |
CDK4 (cyclin D1) | 159 | PV4400 | |
MAPK1 (ERK2) | 159 | PV3313 | |
IGF1R | 138 | PV3250 | |
CDK2/Cyclin A | 137 | ✓ | PV3267 |
KDR (VEGFR2) | 120 | PV3660 | |
KIT | 107 | ✓ | P3081 |
MERTK (cMER) | 107 | PV3627 | |
PTK2 (FAK) | 105 | ✓ | PV3832 |
BCR | 97 | ||
FYN | 95 | ✓ | P3042 |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 101 | PV3814 | |
MAPK3 (ERK1) | 35 | PV3311 | |
SRC | 35 | ✓ | P3044 |
MET (CMET) | 30 | ✓ | PV3143 |
LKB1 | 17 | ||
AKT2 (PKB beta) | 13 | PV3184 | |
YES1 | 13 | A15557 | |
FYN | 11 | ✓ | P3042 |
JAK2 | 10 | ✓ | PV4210 |
LYN A | 9 | ✓ | PV6448 |
PDK1 | 9 | P3001 | |
EGFR (ErbB1) | 8 | ✓ | PV3872 |
MAPK8 (JNK1) | 8 | PV3319 | |
AKT1 (PKB alpha) | 7 | P2999 | |
SIK1 | 7 | ✓ | PV6445 |
SYK | 7 | PV3857 | |
aPKC | 6 | ||
ERN1 | 6 | A30971 | |
FRAP1 (mTOR) | 6 | PV4753 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
With increasing focus on public health and air quality, a renewed importance has been placed on the study of chronic respiratory diseases including asthma, lung cancer and chronic obstructive pulmonary disease (COPD).
Thermo Fisher Scientific offers over 490 purified protein kinases for therapeutic research and over 210 kinases that have been cited in over 3,300 published papers. See the list of kinases for asthma research, chronic obstructive pulmonary disease (COPD) research, and cystic fibrosis research below.
See the full list of mutants and kinases for respiratory disease research
Go to the kinase selection and ordering tool
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
MAPK3 (ERK1) | 218 | PV3311 | |
ROS1 | 209 | PV3814 | |
SRC | 145 | ✓ | P3044 |
MET (CMET) | 108 | ✓ | PV3143 |
EGFR (ErbB1) | 103 | ✓ | PV3872 |
KIT | 70 | ✓ | P3081 |
SYK | 68 | PV3857 | |
JAK2 | 61 | ✓ | PV4210 |
YES1 | 59 | A15557 | |
ABL2 (ARG) | 53 | PV3266 | |
JAK1 | 53 | PV4774 | |
LYN A | 48 | ✓ | PV6448 |
BCR | 36 | ||
FYN | 33 | ✓ | P3042 |
JAK3 | 30 | PV3855 | |
LCK | 30 | P3043 | |
MAPK1 (ERK2) | 30 | PV3313 | |
TYK2 | 30 | PV4790 | |
CSF1R (FMS) | 28 | PV3249 | |
MAPK8 (JNK1) | 28 | PV3319 | |
TEC | 28 | PV3269 | |
AKT1 (PKB alpha) | 26 | P2999 | |
EIF2AK2 (PKR) | 26 | PV4821 | |
FLT3 | 26 | ✓ | PV3182 |
ABL1 | 24 | ✓ | P3049 |
ALK | 24 | ✓ | PV3867 |
TNK2 (ACK) | 23 | PV4807 | |
BTK | 22 | PV3363 | |
MERTK (cMER) | 22 | PV3627 | |
PTK2 (FAK) | 20 | ✓ | PV3832 |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
MAPK3 (ERK1) | 81 | PV3311 | |
EGFR (ErbB1) | 74 | ✓ | PV3872 |
MET (CMET) | 56 | ✓ | PV3143 |
SRC | 42 | ✓ | P3044 |
YES1 | 25 | A15557 | |
EIF2AK2 (PKR) | 20 | PV4821 | |
ROS1 | 20 | PV3814 | |
PTK2 (FAK) | 13 | PV3832 | |
PTK2B (FAK2) | 13 | PV4567 | |
ATM | 11 | ||
MAPK8 (JNK1) | 11 | PV3319 | |
MERTK (cMER) | 11 | PV3627 | |
ABL1 | 10 | ✓ | P3049 |
JAK2 | 10 | ✓ | PV4210 |
RAF1 (cRAF) Y340D Y341D | 10 | ✓ | PV3805 |
ALK | 9 | ✓ | PV3867 |
MAPK1 (ERK2) | 9 | PV3313 | |
TNK2 (ACK) | 9 | PV4807 | |
ABL2 (ARG) | 8 | PV3266 | |
MERTK (cMER) A708S | 8 | PV6325 | |
BMPR2 | 7 | PV6256 | |
ERBB2 (HER2) | 7 | PV3366 | |
IRAK, pelle | 7 | PV4403 | |
SYK | 7 | PV3857 | |
ULK1 | 7 | PV6430 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
No records were found matching your criteria
Protein kinase | Number of citations* | Mutants/variants available? | Cat. No. |
---|---|---|---|
ROS1 | 72 | PV3814 | |
MET (CMET) | 64 | ✓ | PV3143 |
MAPK3 (ERK1) | 56 | PV3311 | |
ABL2 (ARG) | 38 | PV3266 | |
SRC | 36 | ✓ | P3044 |
EGFR (ErbB1) | 35 | ✓ | PV3872 |
YES1 | 27 | A15557 | |
MERTK (cMER) | 20 | PV3627 | |
SGK (SGK1) | 20 | PV3818 | |
Wnk1 | 17 | A33513 | |
OXSR1 | 15 | A30983 | |
EIF2AK2 (PKR) | 14 | PV4821 | |
ERN1 | 14 | A30971 | |
MAPK1 (ERK2) | 12 | PV3313 | |
SYK | 11 | PV3857 | |
Wnk4 | 10 | ||
LKB1 | 9 | ||
PTK2B (FAK2) | 9 | ✓ | PV3832 |
ERBB2 (HER2) | 8 | PV3366 | |
ATM | 7 | ||
Wnk3 | 7 | PV4342 | |
*Reflects the number of published papers discovered from a “common name kinase” + “specific disease area” keyword search in PubMed Central over the period from January 2000 to August 2016. |
For Research Use Only. Not for use in diagnostic procedures.